“You don’t usually get the chance to pick up the entire research-and-development arm of a major company for free,” acknowledges the author of today’s article – but he proceeds to highlight how, in the aftermath of the stock market rout, shares of some biotech companies have been pushed down to the point where investors get those companies’ pipelines “just about for free.” For two such biotechs – as well as a third which may still be a good deal despite having rebounded – CLICK HERE.